Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Net Income (2024 - 2025)

Evommune (EVMN) has disclosed Net Income for 2 consecutive years, with -$28.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income changed N/A to -$28.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$44.8 million, a N/A change, with the full-year FY2025 number at -$77.8 million, down 16.45% from a year prior.
  • Net Income was -$28.3 million for Q4 2025 at Evommune, down from -$16.5 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$16.5 million in Q3 2024 to a low of -$28.3 million in Q4 2025.